RKLB Fundamental Analysis - ROCKET LAB CORP

Name: ROCKET LAB CORP (RKLB) Stock
Brand: ROCKET LAB CORP
Rating: 6.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to RKLB. RKLB was compared to 71 industry peers in the Aerospace & Defense industry. RKLB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RKLB is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

RKLB had negative earnings in the past year.

RKLB had a negative operating cash flow in the past year.

RKLB had negative earnings in each of the past 5 years.

RKLB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -14.89%, RKLB is not doing good in the industry: 74.65% of the companies in the same industry are doing better.

RKLB has a Return On Equity of -33.60%. This is in the lower half of the industry: RKLB underperforms 73.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-14.89%
ROE	-33.6%
ROIC	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of RKLB (29.04%) is better than 66.20% of its industry peers.

The Profit Margin and Operating Margin are not available for RKLB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	29.04%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for RKLB has been increased compared to 1 year ago.

The number of shares outstanding for RKLB has been increased compared to 5 years ago.

Compared to 1 year ago, RKLB has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 18.49 indicates that RKLB is not in any danger for bankruptcy at the moment.

RKLB has a Altman-Z score of 18.49. This is amongst the best in the industry. RKLB outperforms 95.77% of its industry peers.

A Debt/Equity ratio of 0.60 indicates that RKLB is somewhat dependend on debt financing.

The Debt to Equity ratio of RKLB (0.60) is worse than 60.56% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.6
Debt/FCF	N/A
Altman-Z	18.49

ROIC/WACCN/A

WACC9.56%

2.3 Liquidity

RKLB has a Current Ratio of 2.67. This indicates that RKLB is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.67, RKLB is in line with its industry, outperforming 56.34% of the companies in the same industry.

A Quick Ratio of 2.33 indicates that RKLB has no problem at all paying its short term obligations.

RKLB has a Quick ratio of 2.33. This is in the better half of the industry: RKLB outperforms 74.65% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.67
Quick Ratio	2.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for RKLB have decreased strongly by -28.57% in the last year.

The Revenue has grown by 54.37% in the past year. This is a very strong growth!

Measured over the past years, RKLB shows a very strong growth in Revenue. The Revenue has been growing by 55.23% on average per year.

EPS 1Y (TTM)-28.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-62.5%

Revenue 1Y (TTM)54.37%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%36%

3.2 Future

The Earnings Per Share is expected to grow by 32.40% on average over the next years. This is a very strong growth

RKLB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.13% yearly.

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y31.23%

EPS Next 5Y32.4%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y32.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RKLB. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RKLB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RKLB's earnings are expected to grow with 31.23% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.45%

EPS Next 3Y31.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RKLB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET LAB CORP

NASDAQ:RKLB (11/5/2025, 2:54:07 PM)

56.53

-0.04 (-0.07%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-10 2025-11-10/amc

Inst Owners61.26%

Inst Owner Change1.97%

Ins Owners0.64%

Ins Owner Change9.26%

Market Cap27.36B

Revenue(TTM)504.26M

Net Income(TTM)-231314000

Analysts79.05

Price Target59.09 (4.53%)

Short Float %11.54%

Short Ratio2.3

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-1.65%

Min EPS beat(2)-11.38%

Max EPS beat(2)8.09%

EPS beat(4)3

Avg EPS beat(4)3.2%

Min EPS beat(4)-11.38%

Max EPS beat(4)12.21%

EPS beat(8)7

Avg EPS beat(8)8.2%

EPS beat(12)8

Avg EPS beat(12)4.25%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)1.82%

Min Revenue beat(2)-0.99%

Max Revenue beat(2)4.63%

Revenue beat(4)2

Avg Revenue beat(4)0.87%

Min Revenue beat(4)-0.99%

Max Revenue beat(4)4.63%

Revenue beat(8)2

Avg Revenue beat(8)-1.29%

Revenue beat(12)5

Avg Revenue beat(12)-0.34%

Revenue beat(16)8

Avg Revenue beat(16)1.42%

PT rev (1m)26.75%

PT rev (3m)56.75%

EPS NQ rev (1m)-0.18%

EPS NQ rev (3m)-5.84%

EPS NY rev (1m)-0.28%

EPS NY rev (3m)-8.37%

Revenue NQ rev (1m)0.29%

Revenue NQ rev (3m)0.94%

Revenue NY rev (1m)0.56%

Revenue NY rev (3m)2.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	54.25
P/FCF	N/A
P/OCF	N/A
P/B	39.74
P/tB	48.55
EV/EBITDA	N/A

EPS(TTM)-0.45

EYN/A

EPS(NY)-0.17

Fwd EYN/A

FCF(TTM)-0.42

FCFYN/A

OCF(TTM)-0.23

OCFYN/A

SpS1.04

BVpS1.42

TBVpS1.16

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.89%
ROE	-33.6%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	29.04%
FCFM	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.32

Health

		Industry Rank	Sector Rank
Debt/Equity	0.6
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	268.86%
Cap/Sales	18.5%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.67
Quick Ratio	2.33
Altman-Z	18.49

F-Score4

WACC9.56%

ROIC/WACCN/A

Cap/Depr(3y)174.96%

Cap/Depr(5y)206.2%

Cap/Sales(3y)19.28%

Cap/Sales(5y)34.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-28.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-62.5%

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y31.23%

EPS Next 5Y32.4%

Revenue 1Y (TTM)54.37%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%36%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y32.13%

EBIT growth 1Y-28.41%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year51.27%

EBIT Next 3Y41.55%

EBIT Next 5Y31.86%

FCF growth 1Y-70.08%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-50.93%

OCF growth 3YN/A

OCF growth 5YN/A

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

ChartMill assigns a fundamental rating of 3 / 10 to RKLB.

Can you provide the valuation status for ROCKET LAB CORP?

ChartMill assigns a valuation rating of 1 / 10 to ROCKET LAB CORP (RKLB). This can be considered as Overvalued.

How profitable is ROCKET LAB CORP (RKLB) stock?

ROCKET LAB CORP (RKLB) has a profitability rating of 1 / 10.

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?

The Earnings per Share (EPS) of ROCKET LAB CORP (RKLB) is expected to decline by -19.95% in the next year.

ROCKET LAB CORP (RKLB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

Can you provide the valuation status for ROCKET LAB CORP?

How profitable is ROCKET LAB CORP (RKLB) stock?

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?